Dr. Siegall is the Chairman, CEO, and President of Immunome, Inc. Previously he was CEO of Morphimmune, a privately held biotechnology company focused on developing targeted oncology therapeutics, where he oversaw the successful merger of Morphimmune and Immunome. Since the merger in October 2023, Dr. Siegall has raised $355 million in equity financings for the company.
Over his 25+ year career in the biopharmaceutical industry, Dr. Siegall has helped to envision, develop, and commercialize multiple targeted therapies that are used daily to help improve the lives of cancer patients around the world. These include the ADCs ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TIVDAK® (tisotumab vedotin-tftv), and the small molecule TUKYSA® (tucatinib). All four drugs were developed and/or commercialized by Seagen, Inc., which Dr. Siegall co-founded in 1998 and led for nearly 25 years. Pfizer, Inc. acquired Seagen for $43 billion in late 2023.
With a continued passion for helping to improve outcomes and quality of life for cancer patients with unmet medical need, Dr. Siegall is building on and leveraging his expertise to make Immunome a leader in targeted oncology therapeutics innovation.
Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and the National Cancer Institute. He is an author on more than 60 peer-reviewed scientific publications and more than a dozen patents and is the recipient of multiple scientific and biopharmaceutical industry awards. Dr. Siegall currently serves as chairman of the board of directors for Tourmaline Bio, Inc. (Nasdaq: TRML) and as a member of the board of directors of Shattuck Labs, Inc. (Nasdaq: STTK). He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.
What is Clay B. Siegall's net worth?
The estimated net worth of Clay B. Siegall is at least $16.21 million as of March 26th, 2025. Siegall owns 806,736 shares of Immunome stock worth more than $16,207,326 as of December 4th. This net worth evaluation does not reflect any other assets that Siegall may own. Additionally, Siegall receives an annual salary of $1,430,000.00 as CEO at Immunome. Learn More about Clay B. Siegall's net worth.
How old is Clay B. Siegall?
What is Clay B. Siegall's salary?
How do I contact Clay B. Siegall?
Has Clay B. Siegall been buying or selling shares of Immunome?
Clay B. Siegall has not been actively trading shares of Immunome during the last ninety days. Most recently, on Wednesday, March 26th, Clay B. Siegall bought 137,100 shares of Immunome stock. The stock was acquired at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. Learn More on Clay B. Siegall's trading history.
Who are Immunome's active insiders?
Are insiders buying or selling shares of Immunome?
In the last twelve months, Immunome insiders bought shares 5 times. They purchased a total of 311,400 shares worth more than $2,369,895.00. The most recent insider tranaction occured on June, 3rd when Director Jean Jacques Bienaime bought 5,000 shares worth more than $46,900.00. Insiders at Immunome own 7.7% of the company.
Learn More about insider trades at Immunome. Information on this page was last updated on 6/3/2025.
